Company
Headquarters: Taipei, Taiwan
TW$6.23 Billion
TWD as of July 1, 2024
US$191.4 Million
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $121.36 B |
| Regeneron Pharmaceuticals, Inc. | $115.11 B |
| CSL Limited | $95.75 B |
| Marinomed Biotech AG | $75.67 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Medigen Biotechnology Corp. focuses on the development of therapies for liver diseases and cancers in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. The company develops PI-88 (MUPAFOSTAT), which has completed Phase II clinical trial for use as an adjuvant therapy for HCC after curative surgery; and Phase III trial for the adjuvant treatment of patients with hepatitis virus related hepatocellular carcinoma after surgical resection. It also provides OBP-301 that is in a Phase I clinical trials for the treatment of esophageal cancer, and Phase II clinical trials for the treatment of esophageal and gastric cancer. In addition, the company develops human native mAbs for therapeutic applications related to infectious diseases; and molecular diagnostics, vaccine, and generic drugs. Medigen Biotechnology Corp. was founded in 1999 and is headquartered in Taipei, Taiwan.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Medigen Biotechnology Corp has the following listings and related stock indices.
Stock: TWSE: 3176 wb_incandescent